In the BEACON CRC phase III clinical trial, metastatic CRC patients harboring a BRAF exon 15 p.V600E point mutation, with disease progression after one or two previous treatment regimens, were randomized to receive encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (anti-EGFR) or encorafenib and cetuximab, or other treatment approaches, including cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil, and irinotecan). This evidence concerns the gene MAP2K7 and colorectal carcinoma.